The Two Active X Chromosomes in Female ESCs Block Exit from the Pluripotent State by Modulating the ESC Signaling Network  by Schulz, Edda G. et al.
Cell Stem Cell
ArticleThe Two Active X Chromosomes in Female ESCs
Block Exit from the Pluripotent State
by Modulating the ESC Signaling Network
Edda G. Schulz,1,* Johannes Meisig,2,3 Tomonori Nakamura,4,5 Ikuhiro Okamoto,4,5 Anja Sieber,2,3 Christel Picard,1
Maud Borensztein,1 Mitinori Saitou,4,5,6,7 Nils Blu¨thgen,2,3 and Edith Heard1,*
1Mammalian Developmental Epigenetics Group, Institut Curie, CNRS UMR 3215, INSERM U934, Paris 75248, France
2Institute of Pathology, Charite´-Universita¨tsmedizin, 10117 Berlin, Germany
3Integrative Research Institute for the Life Sciences and Institute for Theoretical Biology, Humboldt Universita¨t, 10115 Berlin, Germany
4Department of Anatomy and Cell Biology, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501,
Japan
5JST, ERATO, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan
6Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, Shogoin Yoshida, Sakyo-ku, Kyoto 606-8507, Japan
7Institute for Integrated Cell-Material Sciences, Kyoto University, Yoshida-Ushinomiya-cho, Sakyo-ku, Kyoto 606-8501, Japan
*Correspondence: edda.schulz@curie.fr (E.G.S.), edith.heard@curie.fr (E.H.)
http://dx.doi.org/10.1016/j.stem.2013.11.022SUMMARY
During early development of female mouse embryos,
both X chromosomes are transiently active. X gene
dosage is then equalized between the sexes through
the process of X chromosome inactivation (XCI).
Whether the double dose of X-linked genes in
females compared with males leads to sex-specific
developmental differences has remained unclear.
Using embryonic stem cells with distinct sex chro-
mosome compositions as a model system, we
show that two X chromosomes stabilize the naive
pluripotent state by inhibiting MAPK and Gsk3
signaling and stimulating the Akt pathway. Since
MAPK signaling is required to exit the pluripotent
state, differentiation is paused in female cells as
long as both X chromosomes are active. By prevent-
ing XCI or triggering it precociously, we demonstrate
that this differentiation block is released once XX
cells have undergone X inactivation. We propose
that double X dosage interferes with differentiation,
thus ensuring a tight coupling between X chromo-
some dosage compensation and development.
INTRODUCTION
During early embryogenesis in many mammals, such as mice,
rats, and cows, female embryos developmore slowly thanmales
(Mittwoch, 1993). Since no fetal hormones are produced at these
stages of embryonic development, the observed developmental
sex differences have been attributed to a direct action of
sex-linked genes. Genetic dissection using mice with an XO kar-
yotype revealed that the presence of two X chromosomes con-
tributes to the developmental differences by slowing down
embryogenesis early after implantation into the uterus (Burgoyne
et al., 1995).CeIn somatic tissues, the difference in X chromosome number
between the sexes is compensated for through the process of
X chromosome inactivation (XCI), which ensures chromosome-
wide gene silencing of one X in all female cells (Augui et al.,
2011; Schulz and Heard, 2013). XCI is initiated by upregulation
of the noncoding Xist RNA at the future inactive X, which then
mediates gene silencing in cis. During murine preimplantation
development, Xist expression is imprinted so that the paternal
X is always inactivated. While this imprinted form of XCI is main-
tained in extraembryonic tissues, the paternal X is reactivated in
the inner cell mass (ICM) of the blastocyst, which will give rise to
the embryo. Shortly afterward, one randomly chosen X is inacti-
vated at the epiblast stage. Thus, the two X chromosomes in
female embryos are both active during a short time window
around implantation. Whether (and how) this resulting transient
double dose of X-linked genes affects development in a sex-
specific manner has remained unclear.
In the mouse, which is the best-studied mammal to date, X
inactivation is set up before lineage commitment occurs, at a
point when each cell can give rise to all somatic and germline
cell types and thus is pluripotent. Tight coupling between XCI
and development is thought to be ensured through direct and in-
direct repression of Xist by pluripotency factors such as Oct4,
Nanog, and Rex1, so that XCI is only initiated once these factors
are downregulated during differentiation (Augui et al., 2011).
These regulatory relationships have been studied mostly in
female mouse embryonic stem cell (mESC) lines derived from
the ICM of the blastocyst, which have two active X chromo-
somes and undergo random XCI during in vitro differentiation.
When induced to differentiate, ESCs exit the so-called ground
state of pluripotency, transition through a primed state in which
certain pluripotency factors are downregulated and XCI is initi-
ated, and only then adopt a specific cell fate (Nichols and Smith,
2009). The transition to the primed state is strongly dependent on
autocrine growth factor Fgf4, which signals via the mitogen-acti-
vated protein kinase (MAPK) cascade (Lanner and Rossant,
2010). Through ectopic inhibition of this pathway in combination
with aGsk3 inhibitor (‘‘2i’’ culture conditions), ESCs can bemain-
tained in a pluripotent ground state (Ying et al., 2008), in contrastll Stem Cell 14, 203–216, February 6, 2014 ª2014 Elsevier Inc. 203
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Figure 1. Two X Chromosomes Delay mESC Differentiation
(A) Experimental setup: XX (PGK12.1), XO (derived from PGK12.1), and XY (E14) ESCs, cultured in serum-free medium with 2i and LIF were differentiated into
epiblast-like cells (EpiLC) with Fgf2 and Activin A for 3.5 days. At the indicated time points, mRNA levels were assessed genome wide using Affymetrix mouse
exon microarrays.
(B) Comparison of gene-expression kinetics among XX, XO, and XY mESCs. Heatmaps show similarity with respect to gene-expression levels between the
different cell lines at different time points as measured by the Euclidean distance of all genes that change significantly over time (1,391 genes). Dashed lines
indicate the diagonal and red lines indicate the maximal similarity. Arrows are visual guides that link day 3 on the y axis to the most similar time point on the
x axis.
(C) GSEA for GO terms in genes that show delayed kinetics in XX cells. For each gene, the delay was quantified as the difference of themean derivatives in XX and
XO cells (red line). ‘‘Stem cell maintenance’’ was significantly enriched (FDR < 0.05) and gray lineswith dots indicate the positions of the associated genes. The top
ten GO terms are given in Table S1 and a list of delay scores is provided in Table S2.
(D) PCA of genes annotated with the GO term ‘‘stem cell maintenance.’’ The first two PCs are plotted; circles represent the day of differentiation as indicated. See
Figure S1A and Table S3 for PC loadings.
(legend continued on next page)
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MAPK-Mediated Differentiation Block in XX ESCsto the metastable state found in classical serum-containing me-
dium supplemented with leukemia inhibitory factor (LIF), where
cells fluctuate between the ground state and a primed state
(Graf and Stadtfeld, 2008). Whereas the MAPK and Gsk3 path-
ways destabilize the pluripotent state, the Lif/Stat3 and Pi3K/
Akt signaling pathways are required to maintain self-renewal
and pluripotency (Welham et al., 2011).
In order to investigate the role of X dosage and dosage
compensation in ESCs and differentiation as a model for early
embryonic development, we performed a genome-wide tran-
scriptome comparison of mESC lines with distinct sex chromo-
some compositions (XX, XO, and XY). We found that double X
chromosome dosage stabilizes the pluripotency network and
blocks the exit from the pluripotent state by interfering with the
ESC signaling network, thus resulting in delayed differentiation
of XX mESCs. We further demonstrate that only after X inactiva-
tion has occurred, and only a single dose of X-linked genes
remains, can XX cells efficiently downregulate pluripotency
factors. We propose that two active X chromosomes arrest
differentiation to ensure the coordination of X inactivation and
development, so that differentiation is on hold until X dosage
compensation has been achieved.
RESULTS
Two Active X Chromosomes Block the Exit from the
Pluripotent State
To assess the role of X dosage in early differentiation, we used an
in vitro system in which mESCs are differentiated into epiblast-
like cells (EpiLC) (Guo et al., 2009). The EpiLC transcriptome
has been shown to resemble that of the early epiblast in vivo
(Hayashi et al., 2011), which corresponds to the first stage of em-
bryonic development in which X inactivation occurs in mice. We
compared the differentiation kinetics (starting from 2i culture
conditions, as shown in Ying et al., 2008; see Experimental Pro-
cedures) of three mESC lines with distinct sex chromosome
compositions: a female XX line (Pgk12.1), an XO subclone of
this line that had lost one X (Pgk12.1 E8), and a male XY line
from a related genetic background (E14). At multiple time points
within the first 3.5 days of differentiation (XCI is initiated between
days 1 and 2), we analyzed the transcriptome profiles of these
cells using Affymetrix mouse exon arrays (Figure 1A). When we
compared the overall transcript dynamics, we found that
although the kinetics of the XO and XY cells were similar, the
XX line started to lag behind after the first day of differentiation
(Figure 1B). Its overall transcript levels started to resemble earlier
time points in the XO and XY lines, such that at day 3, XX cells
were comparable to the XO and XY lines at day 2 of differentia-
tion (Figure 1B, middle right, arrows). To decipher which pro-
cesses are delayed in XX cells, we quantified the delay of each
gene and performed a gene set enrichment analysis (GSEA) for
Gene Ontology (GO) terms (Figure 1C; Tables S1 and S2 avail-
able online). The only terms that were significantly enriched(E) Expression kinetics of genes with a strong delay in XX compared with XO and
below the gene name.
(F) Expression kinetics of the genes shown in Figure 1E were assessed in anot
differentiated by LIF withdrawal. The mean and SD of three independent experim
See also and Figure S1 and Tables S1, S2, and S3.
Ceamong those genes with a strong delay in XX cells (GSEA, false
discovery rate [FDR] < 0.05) were ‘‘stem cell maintenance’’ (Fig-
ure 1C, gray lines) and ‘‘stem cell development,’’ suggesting that
the presence of two X chromosomes delays the exit from the
stem cell state. We confirmed this interpretation by analyzing
the expression profiles of the stem cell maintenance factors
through principal component analysis (PCA), which showed
that even though all three cell lines followed similar trajectories,
the XX line started to be delayed by day 1 and seemed to be
almost arrested at day 2 of differentiation (Figures 1D and S1A;
Table S3). The transcript abundances of pluripotency factors
and other delayed genes were similar in all three cell lines during
the first day and then XO and XY cells showed a rapid drop,
whereas levels remained much higher in the XX line (see exam-
ples in Figure 1E). This delayed downregulation of pluripotency
factors was also observed in serum-cultured cells differentiated
by LIF withdrawal (Figure S1B) and after adaptation to 2i condi-
tions for more than ten passages (Figure S1C). To confirm that
indeed the number of X chromosomes was responsible for the
observed delay in differentiation, we tested another XX/XO
mESC line pair (1.8XX/XO, identical genetic backgrounds), and
once more, upon differentiation, the XX cells downregulated all
factors tested with slower kinetics and to a lesser extent than
the XO line (Figure 1F). These results show that the observed X
chromosome-dependent differentiation arrest is not specific to
the mESC line or differentiation system used. Therefore, we
conclude that the presence of two X chromosomes delays differ-
entiation of mESCs.
X Dosage Modulates Signaling Pathways in mESCs
When we analyzed the expression kinetics of a panel of pluripo-
tency-associated genes in XX and XOmESCs, we noticed that in
serum-containing medium, several genes, including well-known
pluripotency factors (but not Rex1 and Oct4), were already
increased in XX cells that were still in the undifferentiated state
(Figures 2A, S1B, and S2A). Since these expression differences
were neutralized in 2i medium (Figure 2B), we hypothesized that
the X chromosome number might affect the pluripotency
network by interfering with the signaling pathways that are in-
hibited in 2i conditions. To test this hypothesis, we analyzed
the output of four pluripotency-associated signal transduction
pathways in Pgk XX and E14 XY mESCs, including the MAPK/
Mek and Gsk3 pathways, which are inhibited in 2i. We first iden-
tified target genes for Mek, Gsk3, Akt, and Stat3 from published
microarray analyses of mESCs treated with pathway inhibitors
and mutant cell lines (see Supplemental Experimental Proce-
dures). We then analyzed the expression of these genes in our
microarray data of undifferentiated cells grown in 2imedium (Fig-
ure 2C, open boxes) and in published RNA sequencing (RNA-
seq) data (Marks et al., 2012), where the same cell lines had
been analyzed in serum culture (Figure 2C, filled boxes). In 2i
culture, target gene expression was only slightly affected by X
dosage, but in serum, Mek and Gsk3 targets were reduced inXY cells measured by microarray. The delay score for each gene is indicated
her XX/XO cell line pair (1.8XX/XO), maintained in serum-based medium and
ents are shown. *p < 0.05, two-sample Student’s t test.
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Figure 2. X Dosage Modulates Signaling Pathways in XX mESCs
(A and B) qPCR quantification of selected pluripotency-associated genes in two different XX/XO cell line pairs (Pgk12.1, 1.8) grown in serum-based medium (A)
and in Pgk XX, XO, and E14 XY mESCs maintained in 2i medium (B).
(C) Target genes of theMek, Gsk3, Akt, and Stat3 pathwayswere identified based on published genome-wide expression analyses upon inhibitor treatments. The
expression ratio of Pgk XX versus E14 XYmESCs grown in 2i medium (open boxes) or serum (filled boxes; RNA-seq data fromMarks et al., 2012) is shown. Boxes
indicate the 25th to 75th percentiles and the central bar represents the median. *p < 0.01 and ***p < 0.0001, Wilcoxon rank-sum test.
(D) Five target genes for each pathway shown in (C) were assessed by qPCR in 1.8 XX and XOmESCs grown in serum-containing ESCmedium. Themean and SD
of nine independent experiments are shown.
(E and F) Phosphorylation levels of Mek, Erk2, Gsk3, Akt, and Stat3 were assessed in XX and XO mESC using Luminex technology (E), and differences were
confirmed by immunoblotting (F).
(G) Schematic description of how Mek inhibition and X dosage affect the MAPK, Gsk3, and Akt pathways.
(legend continued on next page)
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MAPK-Mediated Differentiation Block in XX ESCsXX mESCs 3.3- and 2.6-fold, respectively, whereas Akt targets
were increased 2.7-fold (p < 104, Wilcoxon rank-sum test; Fig-
ure 2C). These X-dosage-dependent effects on target gene
expression were confirmed in RNA-seq data for another XX/XY
cell line pair (A.-V. Gendrel, M. Attia, C.-J. Chen, and N.B., un-
published data) and by quantitative PCR (qPCR) analysis of
five target genes for each pathway in 1.8XX/XO and PgkXX/XO
mESCs, which also exhibited the same trends (Figures 2D and
S2B). We therefore conclude that X dosage inhibits Mek and
Gsk3 signaling, but stimulates the Akt pathway.
To further investigate how X dosage affects signal transduc-
tion, we analyzed the phosphorylation levels of several pathway
components in two XX/XO cell line pairs grown in serum, using
Luminex bead assays (Figure 2E). No significant difference was
observed for Gsk3 and Stat3 phosphorylation, but pMek and
pErk, which are part of the MAPK pathway, as well as pAkt
were increased 2- to 4-fold in XX mESCs (Figure 2E). The differ-
ences in phosphorylation levels of Mek, Erk, and Akt were also
confirmed by immunoblotting (Figure 2F). Although elevated
Akt phosphorylation in XX mESCs is consistent with the
X-dosage-dependent increase of Akt target gene expression
(Figure 2C), the increase inMek and Erk phosphorylation was un-
expected given that theMAPK pathway appeared to be inhibited
by X dosage based on the target gene analysis (Figure 2C). How-
ever, such an increase in Mek phosphorylation when the MAPK
pathway is inhibited has been observed previously (Fritsche-
Guenther et al., 2011; Sturm et al., 2010) and is due to a reduc-
tion of negative feedback regulation, such that proteins that are
upstream in the cascade are deactivated, which then dampens
Mek phosphorylation (see scheme in Figure 2G). To confirm
that this feedback is also operating in mESCs, we treated XO
cells with a Mek inhibitor for 2 days. This treatment strongly
increased Mek phosphorylation to levels comparable to those
observed for XX ESCs (Figure 2H). As expected, phosphorylation
of Erk, which lies downstream of Mek, was decreased upon in-
hibitor treatment (Figure 2H). The fact that X dosage, by contrast,
increases Erk phosphorylation suggests that the inhibition of the
MAPK pathway in XX mESCs occurs downstream of Erk (see
scheme in Figure 2G).
The X-dosage-dependent modulation of Mek, Gsk3, and Akt
target genes could be caused by distinct X-linked loci and/or
arise from signaling crosstalk. In support of the latter possibility,
we found that Mek inhibition increased Akt phosphorylation (Fig-
ure 2I). Moreover, Mek inhibition decreased three out of five
Gsk3 targets tested, whereas inhibition of Gsk3 in turn had no
detectable impact on Mek target genes (Figures S2C and
S2D). Thus, signaling crosstalk whereby the MAPK pathway in-
hibits Akt signaling and promotes Gsk3 target gene expression
might contribute to the variety of X-dosage-dependent effects
on the mESC signaling network we observe. We therefore pro-
pose that one or more X-linked genes interfere with the MAPK
signaling pathway and possibly also the Gsk3 and Akt pathways,
thereby promoting the expression of pluripotency factors and(H–J) Mek inhibition (light blue) for 2 days with PD0325901 (1 mM) increases pMe
mESCs, but reduces pErk.
(K) Kinetics of the MAPK target gene Egr1 during differentiation of XX, XO, and X
withdrawal).
The mean and SD of three to five independent experiments are shown in (E) and
Cethus stabilizing the pluripotent state directly and indirectly via
signaling crosstalk. Consistent with this, Mek inhibition in XO
mESCs was sufficient to increase Prdm14 and Nanog expres-
sion to the levels found in XX mESCs (Figure 2J). Although the
X-dosage effect was neutralized by Mek and Gsk3 inhibition (in
2i), it again became effective once the inhibition was removed
at the onset of differentiation, as judged by the mRNA levels of
the MAPK target gene Egr1 in differentiating XX and XO ESCs
(Figures 2K and S3A). We thus propose that inhibition of MAPK
signaling by X dosage, potentially together with additional mech-
anisms, is responsible for the delayed differentiation of XX
mESCs described above.
Having uncovered an X-dosage-dependent inhibition of the
MAPK pathway in the ESC tissue culture system, we tested
whether two active X chromosomes have similar effects in em-
bryos in vivo. The two X chromosomes in female embryos are
both active for only a short time window of development, around
embryonic day 4.5 (E4.5), shortly after imprinted XCI has been
reversed (Mak et al., 2004; Okamoto et al., 2004). We thus per-
formed single-cell qRT-PCR on E4.5 ICM cells isolated by immu-
nosurgery (Figure S3B). Female epiblast cells, which have two
active X chromosomes, showed a tendency to express lower
levels of the MAPK target gene Egr1 compared with their male
counterparts, whereas Nanog levels appeared to be increased
(Figure S3C). Given the technical challenge of analyzing large
numbers of rather fragile epiblast cells, as well as the substantial
variability between embryos and between cells, these differ-
ences were barely statistically significant (Figure S3C). In sum-
mary, we cannot conclude definitively that double X dosage
inhibits MAPK signaling also in vivo, but the tendency seems
to be the same as in ESCs.
X-Dosage-Dependent MAPK Inhibition Contributes to
DNA Hypomethylation by Reducing Expression
of Dnmt3a/b
In the next step, we investigated a potential link between X
dosage and chromatin modifications, since global DNA methyl-
ation and histone acetylation at X-linked genes have been re-
ported to respond to X dosage (O’Neill et al., 2003; Zvetkova
et al., 2005). Although no major differences could be detected
for histone methylation marks (Figure S4A), DNA methylation
levels differed by 40%–50% between XX and XO/XY mESCs
(Figure S4B). The latter finding is consistent with previous
studies that reported global DNA hypomethylation in XXmESCs,
possibly due to decreased expression of the de novo methyl-
transferases Dnmt3a and Dnmt3b (Habibi et al., 2013; Ooi
et al., 2010; Zvetkova et al., 2005). To understand how X dosage
affects DNA methylation, we analyzed the mRNA expression of
seven genes involved in the regulation of DNA methylation, the
DNA methyltransferases Dnmt1 and Dnmt3a/3b/3l, as well as
three Tet enzyme genes, which are involved in DNA demethyla-
tion (Smith and Meissner, 2013). Two different XX/XO cell line
pairs, maintained in serum-containing medium, exhibited ank, pAkt, Nanog, and Prdm14 levels in Pgk XO mESCs to the levels found in XX
Y mESCs using two different culture/differentiation protocols (EpiLC and LIF
(H)–(K); *p < 0.05, two-sample Student’s t test. See also Figure S2.
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MAPK-Mediated Differentiation Block in XX ESCsapproximately 4-fold reduced expression of Dnmt3a and
Dnmt3b in XX mESCs, a slight reduction in Dnmt3l expression,
and a small increase in Tet2 expression (Figure 3A). X dosage
thereforemainly reduced the expression of de novomethyltrans-
ferases Dnmt3a/b, as shown previously (Zvetkova et al., 2005),
and seems to act at the transcriptional level. Since these XX/
XO differences were only visible in serum culture and had disap-
peared after three to five passages in 2i medium (Figure 3B), we
next tested whether de novo methyltransferases might be regu-
lated by the MAPK pathway. Mek inhibition reduced expression
of Dnmt3a, Dnmt3b, and Dnmt3l consistently in both Pgk XX and
XO mESCs maintained in serum (Figure 3C). We therefore pro-
pose that MAPK inhibition in XX mESCs leads to a reduction of
de novo methyltransferases and thereby contributes to the
known DNA hypomethylation of XX cells. However, additional
mechanisms are likely to be involved, since a recent genome-
wide methylation analysis showed that even in 2i medium,
female ESC lines maintain lower levels of DNA methylation
compared with male lines (Habibi et al., 2013).
To understand whether DNA hypomethylation also affects
transcription in an X-dosage-dependent manner, we analyzed
the transcriptome data we had obtained for undifferentiated
XX, XO, and XY mESCs (Figure 1A). The XX-to-XO and XX-to-
XY expression ratios for the vast majority of autosomal genes
were around 1 (0 in log2 scale), but a fraction of X-dosage-sensi-
tive genes (322 out of 9,338; 3.4%) were expressed at higher
levels in XX mESCs (Figure 3D). These autosomally encoded
X-dosage-sensitive genes were candidates for potential dere-
pression by DNA hypomethylation, as described below. On the
X chromosome, the overwhelming majority of genes showed,
as expected, a 2-fold higher expression in XX mESCs (1 in log2
scale; Figure 3E). Only a small number of X-linked genes (20
out of 355; 5.6%), such as the pluripotency factor Nr0b1/Dax1,
were expressed at similar levels in all three cell lines and thus
seemed to be already dosage compensated in undifferentiated
mESCs, possibly through gene-specific mechanisms (Figure 3E,
blue). In addition, a group of genes on the X chromosome (19 out
of 355; 5.4%) appeared to respond to X dosage even moreFigure 3. DNA Methylation-Mediated Effects of MAPK Inhibition in XX
(A and B) Expression of DNA methylation regulators in two different XX/XO cell lin
maintained in 2i culture conditions (B).
(C) Response of methylation regulators to Mek inhibition (1 mM PD0325901) for 2
(D and E) Transcriptome comparison of undifferentiated XX, XO, and XY mESCs.
ratios are plotted. Gray lines indicate the expected ratios of 0 and 1, respectively.
yellow, red, and orange. Blue indicates the regime in which XX-to-XO/XY ratios ar
analyzed in (G) are labeled with arrows. The number of genes in each category i
(F) Genes that become derepressed upon loss of DNA methylation are enriched f
into four categories depending on whether they were found to be upregulated in
X-dosage-sensitive genes (red) and genes with an increased XX/XO or XX/XY rati
category (n) is indicated above each bar.
(G) DNA methylation measured by mass-spectrometry-based EpiTyper analysi
passages. Levels were assessed at major satellite repeat sequences as well as a
average fraction of methylated CpGs within the analyzed region is plotted.
(H) Expression of Dnmt3a and Dnmt3b as assessed by qPCR during EpiLC differe
than ten passages.
(I) Delayed genes (as in Figure 1C) were selected with different stringency and for e
differentiation of ESCs into neural precursor cells is plotted.
(J) DNA methylation was measured by mass-spectrometry-based EpiTyper anal
time points during differentiation.
(K) Dnmt TKO cells and the parental J1 cell line were differentiated by LIF withdra
The mean and SD of three to six independent experiments are shown; *p < 0.05
Cestrongly than expected (>2-fold increase in XX mESCs; Fig-
ure 3E; Table S4). To investigate whether the X-dosage-sensitive
genes we identified on autosomes and on the X chromosome are
derepressed in XX mESCs due to DNA hypomethylation of their
promoters, we asked whether these genes respond to global
loss of DNA methylation. For this purpose, we used transcrip-
tome data from previously published studies that identified
DNAmethylation-sensitive genes inmESCs using a DNAmethyl-
ation-deficient male Dnmt triple-knockout (TKO) ESC line
(Dnmt1/Dnmt3a/Dnmt3b/) (Tsumura et al., 2006). We
saw that high-confidence DNA methylation-sensitive genes
(identified in at least two studies) were highly enriched for
X-dosage-sensitive genes (Fisher’s exact test, p < 1018; Fig-
ure 3F). This finding was confirmed by the fact that four out of
five of the derepressed genes tested showed lower DNAmethyl-
ation levels at their promoters in XX (Pgk12.1) compared with XO
(Pgk12.1-E8) and XY (E14) mESCs (Figure 3G). These findings
are therefore consistent with the possibility that DNA hypome-
thylation results in derepression of some genes in female
mESCs.
Because the transcriptome and methylation analyses
described above (Figures 3D–3G) were performed after three
to five passages in 2i conditions, which strongly impact global
DNA methylation levels (Ficz et al., 2013; Habibi et al., 2013;
Leitch et al., 2013), we investigated the dynamics of the
serum-to-2i transition. Upon transfer to 2i medium, Dnmt3a/b
levels were reduced and became indistinguishable in XX and
XO mESCs after three to five passages (Figure S4C). Promoter
methylation was progressively lost over eight passages (Fig-
ure S4D) and the associated genes (Gm9, Nxf3, Dazl, and Cd4)
became derepressed (Figure S4E). Since methylation loss
occurred with slower kinetics than Dnmt3a/b downregulation,
XX mESCs still exhibited DNA hypomethylation after three to
five passages in 2i (Figure 3G), although Dnmt3a/b were already
expressed at similar levels in XX and XO cells (Figure 3B). Even
after prolonged culture in 2i, when promoter methylation is
completely lost, all X-dosage-sensitive genes tested showed
higher transcript abundance in XX than in XO mESCsmESCs
e pairs (Pgk12.1, 1.8) in serum-based medium (A) and in XX, XO, and XY ESCs
days in serum-based medium in PgkXX or XO mESCs.
For all expressed autosomal (D) and X-linked genes (E), the XX/XO and XX/XY
Genes with expression ratios significantly higher than expected are colored in
e 0 and X-linked genes might already be dosage compensated. Genes that are
s given in Table S4.
or X-dosage-sensitive genes. DNA methylation-sensitive genes were grouped
Dnmt-TKO mESCs in zero, one, two, or three different studies. The fractions of
o (yellow, orange) were calculated in each group. The number of genes in each
s in XX, XO, and XY ESCs adapted to 2i culture conditions for three to five
t the promoters of selected dosage-sensitive genes (indicated in D and E). The
ntiation of Pgk XX/XO mESCs that had been adapted to 2i conditions for more
ach group the fraction of genes that gain methylation at their promoters during
ysis or by Pyrosequencing at promoters of selected delayed genes at several
wal, and the expression dynamics of selected genes were measured by qPCR.
in two-sample Student’s t test. See also Figure S4 and Table S4.
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nisms must also contribute to gene derepression in XX mESCs.
In summary, we propose that MAPK inhibition in XX mESCs is
responsible for the reduced expression of de novo methyltrans-
ferases, which in turn is associated with DNA hypomethylation.
Together with additional, as yet unidentified pathways, this
mechanism might lead to the derepression of DNA methyl-
ation-sensitive genes that we observe in XX mESCs.
Double X Dosage Delays De Novo DNA Methylation
during Differentiation
We next analyzed the possible role of X dosage in de novo DNA
methylation during differentiation. As transcript levels of
Dnmt3a/b are also decreased in XX compared with XO mESCs
during differentiation (Figures 3H and S4F), reduced de novo
methylation of pluripotency-associated genes might contribute
to their delayed downregulation in XX mESCs. To investigate
this hypothesis, we first assessed whether the genes that are
up- or downregulated with a delay in XX cells are normally sub-
ject to promoter methylation during mESC differentiation. For
this purpose, we compared our data with data from a previous
study in which genome-wide DNAmethylation profiles ofmESCs
and differentiated neural precursor cells were generated (Stadler
et al., 2011). We found that up to 30% of the genes that were
most delayed in differentiating XX mESCs gained de novo
methylation at their promoters during mESC differentiation,
compared with only 3% of all the genes that were up- or down-
regulated (GSEA, p < 103; Figure 3I). For six strongly delayed
genes, we also investigated whether, and to what extent, their
promoters would gain methylation during early differentiation.
Four genes (Esrrb, Prdm14, Tcl1, and Laptm5) showed lower
methylation levels in XX cells during differentiation, albeit to a
variable extent.
Based on these observations, we hypothesized that if
impaired de novo methylation of stem cell genes contributes to
the delayed differentiation of female cells, a DNA methylation-
deficient male mESC line should also display delayed differenti-
ation kinetics compared with its wild-type counterpart. Indeed,
our analysis of the male Dnmt TKO mESC line (Tsumura et al.,
2006) revealed that five out of six delayed genes analyzed
were downregulated with slower kinetics in the Dnmt TKO
mutant compared with the wild-type male parental mESC line
(Figures 3K and S4G). As described in the original study by Tsu-
mura et al. (2006), increased cell death was visible during differ-
entiation of Dnmt TKOmESCs from day 3 onward, but the defect
in downregulation of pluripotency factors was already detectable
by days 1 and 2. Taken together, these findings show that, at
least for a subset of genes, their delayed downregulation in XX
cells is accompanied by a small delay in the appearance of de
novo methylation at their promoters. Given that in male mESCs
defective for de novo methylation the downregulation of pluripo-
tency factors is also impaired, we propose that the delay in XX
ESCs is partly due to reduced expression of de novo methyl-
transferases resulting fromMAPK inhibition by double X dosage.
Ectopic XCI Can Reverse X-Dosage-Dependent MAPK
Inhibition
If indeed a double dose of X-linked genes interferes with differ-
entiation of XX mESCs through inhibition of MAPK signaling and210 Cell Stem Cell 14, 203–216, February 6, 2014 ª2014 Elsevier Increduction of DNA methylation, dosage compensation through X
inactivation should neutralize the resulting sex differences.
Consistent with this, DNA hypomethylation starts to disappear
during ESC differentiation, when XCI is initiated (Figure S4H)
and methylation levels as well as expression of pluripotency-
associated genes become indistinguishable between male and
female epiblast stem cell lines, which are derived from E6.5
embryos that have already completed XCI (Figure S4I; Guo
et al., 2009). To test whether the increased expression of pluri-
potency factors, MAPK inhibition, and DNA hypomethylation
that we observed in XX mESCs are indeed due to double X
dosage, we used a system that allows ectopic induction of X
inactivation by doxycyline treatment due to insertion of a tetra-
cycline-inducible promoter at the transcriptional start site of
the endogenous Xist gene. Previously, this system had only
been used in male ESCs and in embryos (Savarese et al.,
2006; Wutz et al., 2002). We derived a female mESC line hetero-
zygous for the doxycycline-inducible promoter (TX1072; Fig-
ure 4A; see Experimental Procedures). Upon doxycycline treat-
ment, an Xist-coated chromosome could be detected in 70%
of cells and X-linked genes were progressively silenced over
several days (Figures 4B–4D). Interestingly, Xist induction ap-
peared to increase cell proliferation of XX mESCs (E.G.S., un-
published observations). The phosphorylation levels of Mek
were already strongly reduced after 2 days of induction and
resembled the levels found in an XO control cell line (Figure 4E).
Furthermore, Akt phosphorylation approached the reduced
levels of the XO control. Only in the case of pErk was no signif-
icant change observed, presumably due to the small XX/XO dif-
ference in Erk phosphorylation in this particular cell line pair and
to the low abundance of pErk in mESCs (Figure 4E). Global DNA
methylation levels also exhibited a rather small difference of
10% in the TX XX/XO cell line pair (Figure 4F). Nevertheless,
methylation levels in XX cells became indistinguishable from
the XO control upon doxycycline treatment, which was consis-
tent with an increase in Dnmt3a/b expression (Figures 4F and
4G). Similarly, the subset of pluripotency-associated genes
tested that exhibited a >2-fold XX/XO difference (Nanog,
Prdm14, and Tcl1) was significantly decreased after 4–6 days
of Xist induction (Figure 4G). Taken together, these findings
strongly suggest that it is indeed a double dose of X-linked
genes that stabilizes the pluripotent state and promotes
DNA hypomethylation throughmodulation of signaling pathways
in XX mESCs, and that the induction of XCI can overcome
these effects, rendering XX ESCs similar to their XO or XY
counterparts.
Pluripotency Factors and Xist RNA Show Reciprocal
Expression in Single Cells
Next, we tested the hypothesis that during differentiation, XCI
might overcome the XX-dependent differentiation arrest and
facilitate the exit from the pluripotent state. This hypothesis
predicts that cells that have undergone XCI will downregulate
pluripotency factors. Taking advantage of the fact that not all
XX cells undergo XCI during the time course analyzed (Fig-
ure S5A), we tested this hypothesis by single-cell qRT-PCR
(Figure 5A). Using Xist expression to identify cells that had initi-
ated XCI, we found that four out of six of the delayed genes
tested (Esrrb, Prdm14, Tcl1, and Laptm5) were expressed.
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Figure 4. Forced X Inactivation Can Reverse X-Dosage Effects in Undifferentiated XX mESCs
(A) Schematic representation of the TX1072 cell line, in which Xist expression can be induced from the endogenous locus by doxycyline.
(B and C) Kinetics of Xist upregulation (green) and silencing of the X-linked Atrx gene (red) during doxycyline-dependent Xist induction in undifferentiated TX1072
mESCs as assessed by RNA FISH.
(D) Silencing of three X-linked genes upon Xist induction was assessed by Pyrosequencing.
(E) Mek, Erk, and Akt phosphorylation levels were measured by Luminex in the presence (black) and absence (red) of doxycyline and in TX1072 XOmESCs (blue
dotted line). Phosphorylation was normalized to the levels in untreated XX cells (red).
(F) Global DNA methylation levels were assessed in TX1072 XX mESCs with and without 6 days of doxycyline treatment and in TX1072 XO cells using the
Pyrosequencing-based Luminometeric DNA methylation assay (LUMA).
(G) Expression of selected genes was measured by qPCR in the presence (black) and absence (red) of doxycyline and in TX1072 XO mESCs (blue). Expression
was normalized to the levels in untreated XX cells (red). Themean and SD of three to five independent experiments are shown; *p < 0.05 in paired Student’s t test.
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Dnmt3a/b seemed to be expressed with higher probability in
Xist RNA-positive cells (Figure 5B). These differences were
more prominent at day 4 than at day 2 of differentiation, as ex-
pected given that X-linked gene silencing follows Xist RNA up-
regulation by a couple of days, being seen only after day 2 of
differentiation (Chow et al., 2010). Although this finding is
consistent with the idea that X inactivation facilitates differenti-
ation, such a negative correlation between Xist RNA upregula-
tion and pluripotency factor expression could also arise from
the previously described repression of Xist by pluripotency fac-
tors (Augui et al., 2011; Navarro et al., 2008), whereby Xist
would be upregulated preferentially after its repressors had
been silenced.CeX Inactivation Releases the Differentiation Arrest
Exerted by Double X Dosage
In order to provide a direct demonstration that XCI promotes
downregulation of pluripotency factors and thus releases the dif-
ferentiation arrest in XX mESCs, we set out to perturb Xist
expression in differentiating XX ESCs in two ways (Figure 5C).
First, we used the TX1072 cell line described above, in which
Xist upregulation can be induced ectopically, thereby uncoupling
Xist expression from its endogenous regulators. Addition of
doxycycline to the culture medium 1 day prior to the onset of dif-
ferentiation resulted in accelerated Xist upregulation, as well as
in an increased number of cells that underwent XCI (Figures 5D
and S6A). During differentiation, four out of the six previously
identified genes that are delayed in XX cells, in particular thosell Stem Cell 14, 203–216, February 6, 2014 ª2014 Elsevier Inc. 211
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Figure 5. X Inactivation Releases the X-Dosage-Dependent Differentiation Block in XX ESCs
(A) Single-cell qRT-PCR protocol to assess expression patterns of delayed stem cell genes in Xist+ and Xist cells during differentiation of Pgk12.1 XX mESCs.
(B) Expression frequencies for selected genes in Xist+ and Xist cells are shown at day 2 (76 cells, top) and day 4 (108 cells, bottom) of differentiation (for more
information, see Figure S5B). Error bars indicate the 95% confidence interval estimated by bootstrapping. *p < 0.05 in two-tailed Fisher’s exact test.
(C) Approaches employed to perturb X inactivation kinetics: Xist deletion (bottom) and Xist upregulation prior to differentiation through a doxycycline-inducible
promoter (TX1072). Xist upregulation was assessed by RNA FISH (green) together with the X-linked gene Huwe1 (red) to confirm the presence of two X chro-
mosomes in the cell. One representative cell is shown for each condition before (D0) and during (D4) differentiation.
(D) Xist expression in TX1072 cells differentiated in the presence (+Dox) or absence (Dox) of doxycyline (added 1 day prior to differentiation), as assessed by Xist
RNA FISH. The mean and SD of three independent experiments are shown; individual experiments are shown in Figure S6A.
(E) Expression of selected genes was measured by qPCR in the presence (black) and absence (red) of doxycyline and in a TX1072 XO line (blue). Expression was
normalized to the levels in untreated XX cells (red).
(F) Differentiation kinetics of Xist2lox/ and Xist/ mESCs. The kinetics of Xist upregulation in Xist2lox/ cells is indicated as a green dashed line.
The mean and SD of three to five independent experiments are shown; *p < 0.05 in paired (E) or two-sample (F) Student’s t test. See also Figures S5 and S6.
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Figure 6. Model for How X Dosage Stabi-
lizes the Pluripotent State and Blocks Dif-
ferentiation
ESCs can fluctuate between the naive ground
state of pluripotency (left) and a state primed for
differentiation (right). One (or several) X-linked
gene(s) (orange) present as a double dose in
female XX ESCs interfere with the MAPK, Gsk3,
and Akt signaling pathways, which in turn con-
trol pluripotency factors such as Nanog and
Prdm14, and de novo DNA methyltransferases
Dnmt3a/b. Consequently, X dosage stabilizes the pluripotent ground state and promotes DNA hypomethylation. Thus, female mESCs can only properly
exit the pluripotent state after they have upregulated Xist (blue) and undergone X inactivation.
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(Nanog, Prdm14, and Tcl1) were downregulated more strongly
upon Xist induction by doxycycline treatment (Figure 5E),
thereby demonstrating that experimentally accelerating X inacti-
vation promotes a more rapid exit from the stem cell state in XX
cells.
In the second approach, we set out to prevent Xist upregula-
tion and XCI during female mESC differentiation. To this end,
we generated a female mESC line in which Xist is deleted on
both X chromosomes. We derived a female mESC line homozy-
gous for the conditional Xist2lox allele (Csankovszki et al., 1999)
and deleted Xist’s promoter together with its first three exons
by Cre-mediated recombination. Whereas the heterozygous
control line readily underwent XCI, Xist/ cells failed to upregu-
late Xist, but nevertheless retained two X chromosomes in more
than 80%of cells (Figures 5C, bottom, and S6B). During differen-
tiation, Xist/ cells maintained higher levels of three out of six of
the delayed genes tested (Nanog, Esrrb, and Tcl1) compared
with the heterozygous female control line (Figure 5F). These dif-
ferences started to be visible around day 3 of differentiation,
about 1 day after Xist had been upregulated in the control. In
addition, Dnmt3a/b and Egr1 were expressed at lower levels in
Xist/mESCs, presumably because these cells maintain a dou-
ble dose of X-linked genes, which inhibit the MAPK pathway
(Figure S6C).
Taken together, these findings support the hypothesis that XX
status inhibits downregulation of pluripotency factors, and that
once X chromosome dosage compensation is ensured, X inacti-
vation feeds back into the pluripotency network and promotes
differentiation.
DISCUSSION
The findings we present in this study demonstrate that double X
dosage stabilizes the pluripotent state, and that female XX ESCs
cannot complete differentiation until X inactivation has occurred.
In the light of our data, we propose the following model for how X
dosage affects stem cell maintenance and differentiation (Fig-
ure 6): Two active X chromosomes modulate the MAPK, Gsk3,
and Akt signaling pathways, which regulate the pluripotent state.
The resulting reduced MAPK activity in female ESCs shifts the
population toward the naive ground state of pluripotency and
thus increases the transcript levels of pluripotency factors. The
reduced activity of MAPK signaling also results in DNA hypome-
thylation, which we propose participates in the slowed exit from
the pluripotent state. However, DNA methylation-independentCemechanisms are also likely to be involved. Consistent with this
model, we demonstrate, using female ESCs that either accel-
erate or prevent XCI, that the presence of two active X chromo-
somes arrests differentiation of female mESCs until X inactiva-
tion has occurred and only a single dose of X-linked gene
products remains. Until now, the coordination between X inacti-
vation and development was thought to be ensured through
repression of Xist by pluripotency factors, so that X inactivation
would be initiated upon exit from the pluripotent state (Augui
et al., 2011; Navarro et al., 2008). We show here, however, that
X inactivation in turn also promotes differentiation, such that
these two processes mutually regulate each other to ensure a
tight coupling between X inactivation and development.
We show that X dosage affects three pathways that play
important roles in the maintenance of pluripotency and in ESC
differentiation: the MAPK/Erk, Gsk3, and Pi3K/Akt signaling
pathways (Lanner and Rossant, 2010; Welham et al., 2011).
Similar to the effects we observe in female mESCs, differentia-
tion is blocked in cells and embryos deficient for Fgf-MAPK
signaling or with constitutively activate Akt (Kunath et al., 2007;
Lanner et al., 2009; Watanabe et al., 2006). Whether the different
X-dosage-dependent effects are mediated by distinct X-linked
loci or they arise from signaling crosstalk is still an open question.
In principle, Lif signaling, which affects both the Pi3K/Akt and
MAPK/Erk pathways could coordinate their activation (Niwa
et al., 2009; Paling et al., 2004). However, this possibility seems
unlikely since neither phosphorylation nor target gene expres-
sion of Stat3, the main mediator of Lif signaling, is affected by
X dosage (Figures 2C–2E). Instead, we observed that Mek inhibi-
tion increases Akt phosphorylation (Figure 2I), such that MAPK
inhibition could indirectly augment Akt target gene expression.
Although the Akt and Gsk3 signaling pathways in turn could be
coordinated by their common upstream kinase Pi3K (Welham
et al., 2011), X dosage seems to interfere further downstream
in the Gsk3 pathway, since phosphorylation of Gsk3 itself is
not affected by X dosage. The role and mechanisms of crosstalk
in mediating the various X-dosage-dependent effects we
observe, as well as the implication of additional signaling-inde-
pendent mechanisms, remain to be elucidated in the future.
Identifying the X-linked genes that are responsible for the sta-
bilization of the pluripotent state that we have uncovered here
will be challenging, since there are 1,000 genes on the X chro-
mosome, several of which might contribute to the observed ef-
fects. However, we can exclude the involvement of several
known links between the X chromosome and pluripotency. The
pluripotency factor Nr0b1/Dax1 is located on the Xll Stem Cell 14, 203–216, February 6, 2014 ª2014 Elsevier Inc. 213
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manner, probably due to negative feedback regulation (Fig-
ure 3E). The X-linked E3 ubiquitin ligase Rlim/Rnf12, which pro-
motes degradation of the pluripotency factor Zfp42/Rex1 (Gon-
tan et al., 2012), can also be excluded because this link should
rather destabilize the pluripotent state in XX ESCs. The inhibition
of MAPK signaling that we describe here seems to be dominant
over any potential pluripotency-destabilizing effect due to
reduced Rex1 protein levels. Although Rex1 is widely used as
a marker for pluripotent cells, its functional role in pluripotency
and self-renewal is still debated (Kashyap et al., 2009). A well-
known downstream effector of MAPK/Erk signaling, Elk1, is
also located in the X. However, this should stimulate rather
than inhibit MAPK signaling activity in XX ESCs. In human pluri-
potent stem cells (hPSCs), global effects on the transcriptome
and on cell growth have been associated with the presence of
two active X chromosomes and were attributed to increased
Elk1 levels (Bruck et al., 2013). However, a parallel cannot be
madewithmESCs, as the latter requireMAPK inhibition, whereas
hPSCs depend on MAPK stimulation. We did test one potential
inhibitor of MAPK signaling in XX mESCs, the X-linked Erk phos-
phatase Dusp9. However, knockdown and overexpression of
Dusp9 had only aminor effect (data not shown). Another X-linked
locus that could potentially be involved is the ESC-specific Pi3K
activator Eras (Welham et al., 2011), but its contribution to
increased Akt signaling in XX mESCs remains to be explored.
Recently, Prdm14 has been proposed to mediate the MAPK-
dependent repression of Dnmt3a/b and to inhibit Fgf-MAPK
signaling (Ficz et al., 2013; Grabole et al., 2013; Leitch et al.,
2013; Yamaji et al., 2013). Since Prdm14 responds strongly to
X dosage, it could in principle mediate the inhibition of MAPK
signaling that we observe in female mESCs. However, Prdm14
inhibits Fgf-MAPK signaling by repressing the Fgf receptor 2
and thereby reduces Erk phosphorylation (Grabole et al., 2013;
Yamaji et al., 2013), whereas we have shown that X dosage
blocks the pathway downstream of Erk and increases pErk
levels. Therefore, it is likely that upregulation of Prdm14 in XX
mESCs is not the cause of X-dosage-dependent MAPK inhibi-
tion, but rather its consequence, since Prdm14 itself is a target
of the pathway.
Are the drastic effects of X gene dosage that we observe in
ESCs also expected to occur in vivo? Since a double dose of
X-linked genes is only present for 1–2 days in the mouse embryo
(Mak et al., 2004; Okamoto et al., 2004), X-dosage-dependent
effects on pluripotency factors and DNA methylation might be
less pronounced than in the mESC culture system. Thus, X
dosage might only block differentiation in the rare cells that fail
to initiate XCI efficiently, and might have a stronger impact only
during the exit from diapause, a developmental arrest in the
pluripotent ground state that occurs in mice if the mother is still
lactating. Nevertheless, previous studies that compared the
growth of embryos with XX and XO karyotypes reported in vivo
effects of X dosage. XO embryos that carry a paternally derived
X (XpO) inactivate their single X during imprinted XCI, so that their
development is retarded due to functional X nullosomy in extra-
embryonic tissues (Jamieson et al., 1998; Thornhill and Bur-
goyne, 1993). The role of double X dosage can therefore only
be assessed in the XX/XmO comparison. Indeed, embryos with
a single maternally derived X chromosome showed accelerated214 Cell Stem Cell 14, 203–216, February 6, 2014 ª2014 Elsevier Incpostimplantation development (Burgoyne et al., 1995; Thornhill
and Burgoyne, 1993). A later paper reported no significant differ-
ence, but this was probably due to the low number of embryos
analyzed (Jamieson et al., 1998). In light of our results, these ob-
servations raise the question as to how stabilization of the pluri-
potent state in female embryos might affect embryonic growth.
Since transfer of ESCs into ground-state conditions (2i) generally
tends to slow down proliferation (E.G.S., unpublished data),
whereas ectopic XCI in XX mESCs appears to accelerate it, pro-
longed maintenance of the pluripotent state in female embryos
might not only delay their development but also decrease their
growth rate, thus resulting in a weight reduction of postimplanta-
tion embryos with two X chromosomes.
Although the presence of only a single X chromosome accel-
erates development, the persistence of double X dosage after
implantation has detrimental consequences for the embryo
and results in death at around E10 (Takagi and Abe, 1990). To
prevent this, mechanisms have presumably evolved to ensure
that all cells in a female embryo will undergo X inactivation. We
propose that two active X chromosomes block differentiation
in order to guarantee a tight coupling of X chromosome dosage
and development. In differentiating male ESCs, ectopic Xist
expression can initiate gene silencing only during a short time
window in early differentiation (Wutz and Jaenisch, 2000).
Through the X-dosage-dependent differentiation block that we
have discussed here, this time window may be extended in
female cells until X inactivation has occurred. A side effect of
this ‘‘developmental checkpoint’’ would then be a small delay
in the development of female embryos.
EXPERIMENTAL PROCEDURES
Detailed information on the cell lines used, culture and differentiation condi-
tions, DNA methylation profiling, single-cell qRT-PCR on ESCs and E4.5 em-
bryos, RNA fluorescence in situ hybridization (FISH), RNA extraction, reverse
transcription, qPCR, microarray hybridization, and bioinformatic analyses
are available in the Supplemental Experimental Procedures.
Bioinformatic Analyses
For analysis of the microarray time series, a subset of genes that show the
strongest dynamics in expression within the XO and XX time series were
defined (see Supplemental Experimental Procedures). To compare the XX,
XO, and XY time series, the normalized Euclidean distance of the expression
vectors at all time points in different cell lines was calculated after smoothing
the time courses. To compute a score measuring delay, the set of regulated
genes was further restricted to those genes that have a difference smaller
than 1 in log2 expression in undifferentiated XO and XX ESCs. The delay score
was computed by taking the average difference of the absolute numerical time
derivative of the smoothed interpolated XO and XX time series.
GSEAwas used to test for enrichment of gene sets with commonGObiolog-
ical process annotation (Subramanian et al., 2005). GSEA was also applied to
test whether delayed genes gain de novo methylation during differentiation,
using a set of de novo methylated genes, based on genome-wide methylation
profiles of ESCs and differentiated neural precursor cells obtained by Stadler
et al. (2011). Regions that were unmethylated (UMR) in mESCs and fully meth-
ylated (FMR) in neural precursor cells were defined as de novo methylated. If a
100 bp region (50 to 50 bp) surrounding a gene’s transcription start site over-
laps with a de novo methylated region, the gene was defined as de novo
methylated.
To define target gene signatures of pluripotency-associated signaling path-
ways, data from published studies in which specific pathways had been chem-
ically or genetically inhibited (see Supplemental Experimental Procedures;
Table S5 for details) were used. Briefly, for each data set, 150 genes with.
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ture if they were found in the majority of experiments for a given pathway.
Single-Cell qRT-PCR
Single-cell qRT-PCR was performed essentially as described elsewhere (Tang
et al., 2010).
Bio-Plex Assay
The level of phospho-protein expression was analyzed with the Bio-Plex
Protein Array system (Bio-Rad) using a total protein amount of 15 mg per sam-
ple and multiplex assays consisting of the following analytes: p-Erk2 (Thr183/
Tyr185), p-MEK1 (Ser217/Ser221), p-Akt (Ser473), p-Gsk3a/b (Ser21/Ser9),
and p-Stat3 (Tyr705). The assay was performed according to the manufac-
turer’s instructions, and beads and detection antibodies were further diluted
three times.
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